Calcium sensitizers: What have we learned over the last 25 years?

@article{Pollesello2016CalciumSW,
  title={Calcium sensitizers: What have we learned over the last 25 years?},
  author={Piero Pollesello and Zolt{\'a}n Papp and Julius Gy Papp},
  journal={International journal of cardiology},
  year={2016},
  volume={203},
  pages={543-8}
}
The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. Drugs such as cardiac glycosides, cathecolamines, phosphodiestherase inhibitors, and calcium sensitizers have been in turn proposed. However, the number of new chemical entities in this therapeutic field has been surprisingly low, and the current selection of drugs is limited. One of the paradigm shifts in the discovery for new inotropes was to focus on… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 100 references

L

  • J. P. Bakkehaug, A. B. Kildal, E. T. Engstad, N. Boardman, T. Næsheim
  • Rønning, et al., The myosin activator omecamtiv…
  • 2015

R

  • B. H. Greenberg, W. Chou, K. G. Saikali
  • Escandón, J.H. Lee, M.M. Chen, et al., Safety and…
  • 2015

The myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac ef fi ciency mediated by resting myosin ATPase activity

  • J. R. Teerlink, C. P. Clarke, K. G. Saikali, J. H. Lee, M. M. Chen, R. D. Escandon
  • Circ . Heart Fail .
  • 2015

Similar Papers

Loading similar papers…